Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2015

View Archived Issues

Immuron and Immune Biologics sign agreement on IMM-124-E for alcohol toxicity

OncoMed doses first patient in phase I trial of OMP-305B83

ProNAi begins phase II trial of PNT-2258 in diffuse large B-cell lymphoma

Azacytidine modulates lenalidomide cytotoxicity in the treatment of B-cell lymphoma

Galapagos begins phase II trial of GLPG-1205 in ulcerative colitis

Cardio3 BioSciences acquires Celdara Medical's OnCyte immuno-oncology cell therapy business

23andMe and Genentech to analyze genomic data for Parkinson's disease

New proteasome inhibitors show efficacy in vitro and in vivo

FDA approves SynCardia Total Artificial Heart for destination therapy study

Alexion reports results from phase II trial of eculizumab in prevention of transplant rejection

Newly described PIEZO1 mutation causes hereditary xerocytosis

FDA awards QIDP designation to Achaogen's plazomicin

Lytix Biopharma discloses novel kinase inhibitors

Janssen patents novel BACE inhibitors

4SC Discovery patent reports new DURK1B inhibitors for cancer

New BRD4 inhibitors designed by Bayer

Scientists at MyoKardia prepares novel agents for cardiomyopathy

CytRx reports interim phase II aldoxorubicin data in HIV-related Kaposi's sarcoma

Infinity Pharmaceuticals reports topline data from phase II duvelisib trial in RA

EMA accepts alirocumab MAA for review

Shire to acquire NPS Pharmaceuticals

Chimerix updates status of brincidofovir development

Biogen Idec discloses phase II trial results for BIIB-033 in acute optic neuritis

BTG acquires PneumRx

Argos Therapeutics reports results from phase IIb trial of AGS-004 in HIV-1 infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...